New York, NY, June 1, 2012 – Scientists from the Ludwig Institute for Cancer Research (LICR) will share research findings from more than a dozen studies both as posters and as part of the published proceedings during the Annual Meeting of the American Society of Clinical Oncology (ASCO) taking place June 1-5 at McCormick Place in Chicago, Ill.
"Since its inception, the Ludwig Institute has been committed to translating promising discoveries from its basic research program into the clinic and eventually into novel therapies for cancer patients," said Andrew Simpson, Ph.D., Scientific Director for the Ludwig Institute for Cancer Research. "Research presented at ASCO by our scientists helps advance the scientific dialogue, which we hope will ultimately lead to new cancer treatments."
Institute abstracts to be presented during poster sessions at the ASCO annual meeting include:
About the Ludwig Institute for Cancer Research
LICR is an international non-profit organization committed to improving the understanding and control of cancer through integrated laboratory and clinical discovery. Leveraging its worldwide network of investigators and the ability to sponsor and conduct its own clinical trials, the Institute is actively engaged in translating its discoveries into applications for patient benefit. Since its establishment in 1971, the Institute has expended more than $1.5 billion on cancer research.